Genetics and Coronary Heart Disease

  • Jennifer L. Hall
  • Ryan J. Palacio
  • Eric M. Meslin


Coronary heart disease (CHD) is the single leading cause of death in America, accounting for about one of every five deaths [1]. Family history of premature parental CHD is associated with a twofold increased risk of cardiovascular disease, making it vital that providers know their patients’ histories. For patients who do not know their family history, genetic testing is being considered as a means to someday fill this gap and will also increase the focus on prevention, provide better diagnostics, and help direct treatment options. This chapter summarizes findings about genes associated with CHD and raises practical and ethical issues that need to be addressed as this field of genetics evolves and before genetic testing at clinics becomes commonplace.


Coronary Heart Disease Human Genome Project Platelet Volume Tiotropium Bromide Cytochrome P450 Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–181.PubMedCrossRefGoogle Scholar
  2. 2.
    Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Lloyd-Jones DM, Nam BH, D’Agostino Sr RB, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Murabito JM, Nam BH, Pencina MJ, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2005;294(24):3117–23.PubMedCrossRefGoogle Scholar
  5. 5.
    McPherson R. Chromosome 9p21 and coronary artery disease. N Engl J Med. 2010;362(18):1736–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation. 1984;69(6):1065–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol. 1991;67(11):933–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Colditz GA, Stampfer MJ, Willett WC, et al. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol. 1986;123(1):48–58.PubMedGoogle Scholar
  9. 9.
    Friedlander Y, Kark JD, Stein Y. Family history of myocardial infarction as an independent risk factor for coronary heart disease. Br Heart J. 1985;53(4):382–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Friedlander Y, Kark JD, Stein Y. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97(2):155–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Jousilahti P, Puska P, Vartiainen E, Pekkanen J, Tuomilehto J. Parental history of premature coronary heart disease: an independent risk factor of myocardial infarction. J Clin Epidemiol. 1996;49(5):497–503.PubMedCrossRefGoogle Scholar
  12. 12.
    Khaw KT, Barrett-Connor E. Family history of stroke as an independent predictor of ischemic heart disease in men and stroke in women. Am J Epidemiol. 1986;123(1):59–66.PubMedGoogle Scholar
  13. 13.
    Leander K, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U. Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: results from the Stockholm Heart Epidemiology Program (SHEEP). Epidemiology. 2001;12(2):215–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Myers RH, Kiely DK, Cupples LA, Kannel W. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120(4):963–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Phillips AN, Shaper AG, Pocock SJ, Walker M. Parental death from heart disease and the risk of heart attack. Eur Heart J. 1988;9(3):243–51.PubMedGoogle Scholar
  16. 16.
    Pohjola-Sintonen S, Rissanen A, Liskola P, Luomanmaki K. Family history as a risk factor of coronary heart disease in patients under 60 years of age. Eur Heart J. 1998;19(2):235–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Roncaglioni MC, Santoro L, D’Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation. 1992;85(6):2065–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104(4):393–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol. 1984;4(4):793–801.PubMedCrossRefGoogle Scholar
  20. 20.
    Sholtz RI, Rosenman RH, Brand RJ. The relationship of reported parental history to the incidence of coronary heart disease in the Western Collaborative Group Study. Am J Epidemiol. 1975;102(4):350–6.PubMedGoogle Scholar
  21. 21.
    Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk associated with various definitions of family history of coronary heart disease. The Newcastle Family History Study II. Am J Epidemiol. 1998;147(12):1133–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Thelle DS, Forde OH. The cardiovascular study in Finnmark county: coronary risk factors and the occurrence of myocardial infarction in first degree relatives and in subjects of different ethnic origin. Am J Epidemiol. 1979;110(6):708–15.PubMedGoogle Scholar
  23. 23.
    Williams RR, Hunt SC, Heiss G, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. 2001;87(2):129–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Bensen JT, Liese AD, Rushing JT, et al. Accuracy of proband reported family history: the NHLBI Family Heart Study (FHS). Genet Epidemiol. 1999;17(2):141–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Centers for Disease Control and Prevention (CDC). Awareness of family health history as a risk factor for disease – United States, 2004. MMWR Morb Mortal Wkly Rep. 2004;53(44):1044–7.Google Scholar
  26. 26.
    Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003;300(5617):286–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.PubMedCrossRefGoogle Scholar
  28. 28.
    Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375(9725):1525–35.PubMedCrossRefGoogle Scholar
  30. 30.
    The human genome at ten [editorial]. Nature. 2010;464:649–50.Google Scholar
  31. 31.
    Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website ( Heart Rhythm. 2009;6(9):1335–41.
  32. 32.
    Ryden L, Standl E, Bartnik M, et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death–executive summary. Rev Port Cardiol. 2007;26(11):1213–74.PubMedGoogle Scholar
  33. 33.
    Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150(2):65–72.PubMedGoogle Scholar
  34. 34.
    Evans JP. Recreational genomics; what’s in it for you? Genet Med. 2008;10(10):709–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Caulfield T. Underwhelmed: hyperbole, regulatory policy, and the genetic revolution. McGill LJ. 2000;45:437.Google Scholar
  36. 36.
    Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491–3.PubMedCrossRefGoogle Scholar
  37. 37.
    McPherson R, Pertsemlidis A, Kavasla N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Schunkert H, Gotz A, Braund P, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation. 2008;117(13):1675–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Anderson JL, Horne BD, Kolek MJ, et al. Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J. 2008;156(6):1155–62. e2.PubMedCrossRefGoogle Scholar
  40. 40.
    Assimes TL, Knowles JW, Basu A, et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum Mol Genet. 2008;17(15):2320–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Baudhuin LM. Genetics of coronary artery disease: focus on genome-wide association studies. Am J Transl Res. 2009;1(3):221–34.PubMedGoogle Scholar
  42. 42.
    Abdullah KG, Li L, Shen GQ, et al. Four SNPS on chromosome 9p21 confer risk to premature, familial CAD and MI in an American Caucasian population (GeneQuest). Ann Hum Genet. 2008;72(Pt 5):654–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Samani NJ, Deloukas P, Erdmann J, et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol. 2009;29(5):774–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Holdt LM, Beutner F, Scholz M, et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol. 2010;30(3):620–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Ensrud K, Grimm Jr RH. The white blood cell count and risk for coronary heart disease. Am Heart J. 1992;124(1):207–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477–82.PubMedCrossRefGoogle Scholar
  48. 48.
    Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis. 2004;172(1):1–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41(11):1182–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Erdmann J, Grosshennig A, Braund PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41(3):280–2.PubMedCrossRefGoogle Scholar
  51. 51.
    Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet. 2009;41(11):1191–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39(6):724–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–94.PubMedCrossRefGoogle Scholar
  54. 54.
    Scuteri A, Sanna S, Chen WM, et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007;3(7):e115.PubMedCrossRefGoogle Scholar
  55. 55.
    Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586–613.PubMedCrossRefGoogle Scholar
  56. 56.
    Lindgren CM, Heid IM, Randall JC, et al. Genome-wide association scan meta-analysis identifies three loci influencing adiposity and fat distribution. PLoS Genet. 2009;5(6):e1000508.PubMedCrossRefGoogle Scholar
  57. 57.
    Renstrom F, Payne F, Nordstrom A, et al. Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. Hum Mol Genet. 2009;18(8):1489–96.PubMedCrossRefGoogle Scholar
  58. 58.
    Walters RG, Jacquemont S, Valsesia A, et al. A new highly penetrant form of obesity due to deletions on chromosome 16p11.2. Nature. 2010;463(7281):671–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009;5(11):e1000730.PubMedCrossRefGoogle Scholar
  60. 60.
    Cohen JC, Boerwinkle E, Mosley Jr TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358(12):1240–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40(2):189–97.PubMedCrossRefGoogle Scholar
  63. 63.
    Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56–65.PubMedCrossRefGoogle Scholar
  64. 64.
    Cho YS, Go MJ, Kim YJ, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet. 2009;41(5):527–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Org E, Eyheramendy S, Juhanson P, et al. Genome-wide scan identifies CDH13 as a novel susceptibility locus contributing to blood pressure determination in two European populations. Hum Mol Genet. 2009;18(12):2288–96.PubMedCrossRefGoogle Scholar
  66. 66.
    Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2009;41(1):35–46.PubMedCrossRefGoogle Scholar
  67. 67.
    Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105–16.PubMedCrossRefGoogle Scholar
  68. 68.
    Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28.PubMedCrossRefGoogle Scholar
  69. 69.
    Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Walley AJ, Asher JE, Froguel P. The genetic contribution to non-syndromic human obesity. Nat Rev Genet. 2009;10(7):431–42.PubMedCrossRefGoogle Scholar
  72. 72.
    Heard-Costa NL, Zillikens MC, Monda KL, et al. NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet. 2009;5(6):e1000539.PubMedCrossRefGoogle Scholar
  73. 73.
    Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677–87.PubMedCrossRefGoogle Scholar
  74. 74.
    Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666–76.PubMedCrossRefGoogle Scholar
  76. 76.
    American Diabetes Association. Diabetes statistics (data from the 2007 National Diabetes Fact Sheet). Accessed 19 July 2010.
  77. 77.
    Evans BJ. What will it take to reap the clinical benefits of pharmacogenomics? Food Drug Law J. 2006;61(4):753–94.PubMedGoogle Scholar
  78. 78.
    Evans BJ, Flockhart DA, Meslin EM. Creating incentives for genomic research to improve targeting of therapies. Nat Med. 2004;10(12):1289–91.PubMedCrossRefGoogle Scholar
  79. 79.
    Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels. Accessed 22 July 2010.
  80. 80.
    Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–6.PubMedCrossRefGoogle Scholar
  81. 81.
    IMS Health. Top 10 Global Products – 2007. Published 26 Feb 2008. Accessed 22 July 2010.
  82. 82.
    RxList, Inc. Top 200 Drugs – US Only. Accessed 19 July 2010.
  83. 83.
    Ingelman-Sundberg M, Sim SC. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun. 2010;396(1):90–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106–12.PubMedCrossRefGoogle Scholar
  85. 85.
    Klein TE, Altman RB, Ericksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2008;51(8):843–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285–93.PubMedCrossRefGoogle Scholar
  88. 88.
    Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation. 2010;121(4):481–3.PubMedCrossRefGoogle Scholar
  89. 89.
    Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.PubMedCrossRefGoogle Scholar
  90. 90.
    Evans BJ, Flockhart DA. The unfinished business of U.S. drug safety regulation. Food Drug Law J. 2006;61(1):45–63.PubMedGoogle Scholar
  91. 91.
    Evans BJ. Seven pillars of a new evidentiary paradigm: the Food, Drug, and Cosmetic Act enters the genomic era. Notre Dame L Rev. 2009;85:2419–524.Google Scholar
  92. 92.
    Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408–16.PubMedCrossRefGoogle Scholar
  93. 93.
    Caulfield T. Popular media, biotechnology, and the cycle of hype. Hous J Health L & Pol’y. 2004;5:213.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jennifer L. Hall
    • 1
  • Ryan J. Palacio
    • 2
  • Eric M. Meslin
    • 3
  1. 1.Department of Medicine, Lillehei Heart InstituteUniversity of MinnesotaMinneapolisUSA
  2. 2.Department of AnesthesiologyUniversity of Minnesota Medical SchoolMinneapolisUSA
  3. 3.Indiana University School of MedicineIndianapolisUSA

Personalised recommendations